Advanced

Absorbed Doses and Risk Estimates of (211)At-MX35 F(ab')2 in Intraperitoneal Therapy of Ovarian Cancer Patients.

Cederkrantz, Elin; Andersson, Hakan; Bernhardt, Peter; Back, Tom; Hultborn, Ragnar; Jacobsson, Lars; Jensen, Holger; Lindegren, Sture; Ljungberg, Michael LU and Magnander, Tobias, et al. (2015) In International Journal of Radiation Oncology, Biology, Physics 93(3). p.569-576
Abstract
Purpose: Ovarian cancer is often diagnosed at an advanced stage with dissemination in the peritoneal cavity. Most patients achieve clinical remission after surgery and chemotherapy, but approximately 70% eventually experience recurrence, usually in the peritoneal cavity. To prevent recurrence, intraperitoneal (i.p.) targeted a therapy has been proposed as an adjuvant treatment for minimal residual disease after successful primary treatment. In the present study, we calculated absorbed and relative biological effect (RBE)-weighted (equivalent) doses in relevant normal tissues and estimated the effective dose associated with i.p. administration of At-211-MX35 F(ab')(2). Methods and Materials: Patients in clinical remission after salvage... (More)
Purpose: Ovarian cancer is often diagnosed at an advanced stage with dissemination in the peritoneal cavity. Most patients achieve clinical remission after surgery and chemotherapy, but approximately 70% eventually experience recurrence, usually in the peritoneal cavity. To prevent recurrence, intraperitoneal (i.p.) targeted a therapy has been proposed as an adjuvant treatment for minimal residual disease after successful primary treatment. In the present study, we calculated absorbed and relative biological effect (RBE)-weighted (equivalent) doses in relevant normal tissues and estimated the effective dose associated with i.p. administration of At-211-MX35 F(ab')(2). Methods and Materials: Patients in clinical remission after salvage chemotherapy for peritoneal recurrence of ovarian cancer underwent i.p. infusion of (211)AtMX35 F(ab')(2). Potassium perchlorate was given to block unwanted accumulation of At-211 in thyroid and other NIS-containing tissues. Mean absorbed doses to normal tissues were calculated from clinical data, including blood and i.p. fluid samples, urine, gamma-camera images, and single-photon emission computed tomography/computed tomography images. Extrapolation of preclinical biodistribution data combined with clinical blood activity data allowed us to estimate absorbed doses in additional tissues. The equivalent dose was calculated using an RBE of 5 and the effective dose using the recommended weight factor of 20. All doses were normalized to the initial activity concentration of the infused therapy solution. Results: The urinary bladder, thyroid, and kidneys (1.9, 1.8, and 1.7 mGy per MBq/L) received the 3 highest estimated absorbed doses. When the tissue- weighting factors were applied, the largest contributors to the effective dose were the lungs, stomach, and urinary bladder. Using 100 MBq/L, organ equivalent doses were less than 10% of the estimated tolerance dose. Conclusion: Intraperitoneal At-211-MX35 F(ab')2 treatment is potentially a well-tolerated therapy for locally confined microscopic ovarian cancer. Absorbed doses to normal organs are low, but because the effective dose potentially corresponds to a risk of treatment-induced carcinogenesis, optimization may still be valuable. (C) 2015 Elsevier Inc. All rights reserved. (Less)
Please use this url to cite or link to this publication:
author
, et al. (More)
(Less)
organization
publishing date
type
Contribution to journal
publication status
published
subject
in
International Journal of Radiation Oncology, Biology, Physics
volume
93
issue
3
pages
569 - 576
publisher
Elsevier
external identifiers
  • wos:000361879700013
  • scopus:84942333306
  • pmid:26460999
ISSN
0360-3016
DOI
10.1016/j.ijrobp.2015.07.005
language
English
LU publication?
yes
id
1305e206-fce0-4786-b5d0-8e45bc1a18ee (old id 8058448)
date added to LUP
2015-10-23 12:06:59
date last changed
2017-05-21 03:00:29
@article{1305e206-fce0-4786-b5d0-8e45bc1a18ee,
  abstract     = {Purpose: Ovarian cancer is often diagnosed at an advanced stage with dissemination in the peritoneal cavity. Most patients achieve clinical remission after surgery and chemotherapy, but approximately 70% eventually experience recurrence, usually in the peritoneal cavity. To prevent recurrence, intraperitoneal (i.p.) targeted a therapy has been proposed as an adjuvant treatment for minimal residual disease after successful primary treatment. In the present study, we calculated absorbed and relative biological effect (RBE)-weighted (equivalent) doses in relevant normal tissues and estimated the effective dose associated with i.p. administration of At-211-MX35 F(ab')(2). Methods and Materials: Patients in clinical remission after salvage chemotherapy for peritoneal recurrence of ovarian cancer underwent i.p. infusion of (211)AtMX35 F(ab')(2). Potassium perchlorate was given to block unwanted accumulation of At-211 in thyroid and other NIS-containing tissues. Mean absorbed doses to normal tissues were calculated from clinical data, including blood and i.p. fluid samples, urine, gamma-camera images, and single-photon emission computed tomography/computed tomography images. Extrapolation of preclinical biodistribution data combined with clinical blood activity data allowed us to estimate absorbed doses in additional tissues. The equivalent dose was calculated using an RBE of 5 and the effective dose using the recommended weight factor of 20. All doses were normalized to the initial activity concentration of the infused therapy solution. Results: The urinary bladder, thyroid, and kidneys (1.9, 1.8, and 1.7 mGy per MBq/L) received the 3 highest estimated absorbed doses. When the tissue- weighting factors were applied, the largest contributors to the effective dose were the lungs, stomach, and urinary bladder. Using 100 MBq/L, organ equivalent doses were less than 10% of the estimated tolerance dose. Conclusion: Intraperitoneal At-211-MX35 F(ab')2 treatment is potentially a well-tolerated therapy for locally confined microscopic ovarian cancer. Absorbed doses to normal organs are low, but because the effective dose potentially corresponds to a risk of treatment-induced carcinogenesis, optimization may still be valuable. (C) 2015 Elsevier Inc. All rights reserved.},
  author       = {Cederkrantz, Elin and Andersson, Hakan and Bernhardt, Peter and Back, Tom and Hultborn, Ragnar and Jacobsson, Lars and Jensen, Holger and Lindegren, Sture and Ljungberg, Michael and Magnander, Tobias and Palm, Stig and Albertsson, Per},
  issn         = {0360-3016},
  language     = {eng},
  number       = {3},
  pages        = {569--576},
  publisher    = {Elsevier},
  series       = {International Journal of Radiation Oncology, Biology, Physics},
  title        = {Absorbed Doses and Risk Estimates of (211)At-MX35 F(ab')2 in Intraperitoneal Therapy of Ovarian Cancer Patients.},
  url          = {http://dx.doi.org/10.1016/j.ijrobp.2015.07.005},
  volume       = {93},
  year         = {2015},
}